Research Article

Distribution and Antimicrobial Susceptibility Pattern of Bacterial Pathogens Causing Urinary Tract Infection in Urban Community of Meerut City, India

Devanand Prakash and Ramchandra Sahai Saxena

Department of Botany, Meerut College, Meerut, Uttar Pradesh 250001, India

Correspondence should be addressed to Devanand Prakash; botanicalsmcm@gmail.com

Received 17 July 2013; Accepted 12 September 2013

1. Introduction

Urinary tract infection (UTI) is the commonest bacterial infectious disease in community practice with a high rate of morbidity and financial cost. It has been estimated that 150 million people were infected with UTI per annum worldwide which costing global economy more than 6 billion US dollars [1]. UTIs is described as a bacteriuria with urinary symptoms [2]. UTI can affect lower and sometimes both lower and upper urinary tracts. The term cystitis has been used to define the lower UTI infection and is characterized by symptoms such as dysuria, frequency, urgency, and suprapubic tenderness. The presence of the lower UTI symptoms does not exclude the upper UTI which is often present in most UTI cases [3]. The treatment of UTI can be classified into uncomplicated and complicated on the basis of their choice of treatment [4]. UTI is more common in females than in males as female urethra structurally found less effective for preventing the bacterial entry [5]. It may be due to the proximity of the genital tract and urethra [6] and adherence of urothelial mucosa to the mucopolysaccharide lining [7]. The other main factors which make females more prone to UTI are pregnancy and sexual activity [8]. In pregnancy, the physiological increase in plasma volume and decrease in urine concentration develop glycosuria in up to 70% women which ultimately leads to bacterial growth in urine [9]. Also in the nonpregnant state the uterus is situated over the bladder whereas in the pregnant state the enlarged uterus affects the urinary tract [10]. Sexual activity in females also increases the risk of urethra contamination as the bacteria could be pushed into the urethra during sexual intercourse as well as bacteria being massaged up the urethra into the bladder during child birth [11, 12]. Using a diaphragm also causes UTI as it pushes against the urethra and makes...
the urethra unable to empty the bladder completely and the small concentration of urine left in the bladder leads to the growth of bacteria which ultimately causes UTI [13]. The spectrum of bacteria causing complicated UTI is much broader than that of those causing uncomplicated UTI. However, the most commonly encountered microorganisms are Gram negative bacteria including *Escherichia coli*, *Citrobacter* spp., *Enterobacter aerogenes*, *Pseudomonas aeruginosa*, and *Proteus vulgaris* whereas *Klebsiella* spp., *Staphylococcus aureus*, and *Salmonella* spp. are found rarely [14].

Increasing multidrug resistance in bacterial uropathogens is an important and emerging public health problem. The Infectious Disease Society of America (IDSA) identified some microorganisms for new effective therapies. Those microorganisms were called “ESKAPE pathogens” which include *Enterococcus faecium*, *S. aureus*, *Klebsiella* spp., *Acinetobacter* spp., *Pseudomonas* spp., and *Enterobacter* spp. Increasing drug resistance in UTI needs regular monitoring of the antibiotic susceptibility of uropathogens in a particular area. Various factors such as the type of UTI (complicated or uncomplicated), gender, age, and previous history of antibiotic therapy of each UTI patient should also be considered to find out the correct global data on susceptibility [15]. The distribution of antimicrobial susceptibility data of UTI-causing microorganisms changes from time to time and from place to place [13]. The susceptibility data provided by regional microbiology laboratories helps to choose the empirical choice of antimicrobials to treat UTI; however, these conditions are limited to complicated UTI as the samples of uncomplicated UTI are rarely sent to laboratories [16, 17]. Generally, the antimicrobial treatment is initiated before the laboratories results which may lead to the frequent misuse of antibiotics [18]. The resistance pattern of community acquired uropathogens has not been extensively studied in India [19–21]. To the best of our knowledge, no data regarding the bacterial resistance in UTIs from Meerut District (Uttar Pradesh), India, has been documented. Since most UTIs are treated empirically, the criteria for the selection of antimicrobial agents should be determined on the basis of the most likely pathogen and its expected resistance pattern in a geographic area. Therefore there is a need for periodic monitoring of etiologic agents of UTI and their resistance pattern in the community.

This study was undertaken in view of paucity of reports of UTIs in patients of Meerut District (Uttar Pradesh), India. The aim of the study is to determine the prevalence of UTI in male and female patients as well as the effect of gender and age on its prevalence. The UTI-causing microorganisms, their distribution among different ages and genders, and their antimicrobial susceptibility will also be determined.

2. Material and Methods

2.1. Study Area. The study was carried out in the microbiology laboratory of the Department of Botany, Meerut College, Meerut (Uttar Pradesh), India. The urine samples were collected from the OPDs (outpatients departments) section of three major hospitals (Meerut Kidney Hospital, Pyarelal Hospital, and Jaswant Rai Hospital) of Meerut city. These sample collection sites were chosen as they mostly covered the urban area of the city. The duration of the study was one and a half year from July 2011 to January 2013.

2.2. Study Population. The urine samples of 288 patients, comprised of 148 males and 140 females, who attended the outpatient departments (OPDs) of three hospitals and had clinical evidence of urinary tract infection, determined by treating physicians, were included in this study. The age of patients included in the study ranged from 15 to ≥48 years. Patients with history of hospital admission a week before their presentation in OPDs were excluded from the study to rule out hospital-acquired infections. The patients on antibiotic therapy were also excluded from the study.

2.3. Sample Collection. Clean catch midstream urine was collected from each patient into a 20 mL calibrated sterile screw-capped universal container which was distributed to the patients. The specimens were labeled, transported to the laboratory, and analyzed within 6 hours. In each container boric acid (0.2 mg) was added to prevent the growth of bacteria in urine samples. All patients were well instructed on how to collect sample aseptically prior to sample collection to avoid contaminations from urethra. Verbal informed consent was obtained from all patients prior to specimen collection. The study was conducted after due ethical approval which was subjected to the hospital administrations.

2.4. Sample Processing. A calibrated loop method was used for the isolation of bacterial pathogens from urinary samples. A sterile 4.0 mm platinum wired calibrated loop was used which delivered 0.001 mL of urine. A loopful urine sample was plated on Cystine-Lactose-Electrolyte Deficient (CLED) agar, MacConkey agar, and blood agar medium (Hi Media Laboratories, Mumbai, India). The inoculated plates were incubated at 37°C for 24 h and for 48 h in negative cases. The number of isolated bacterial colonies was multiplied by 1000 for the estimation of bacterial load/mL of the urine sample. A specimen was considered positive for UTI if an organism was cultured at a concentration of ≥10^5 cfu/mL or when an organism was cultured at a concentration of 10^4 cfu/mL and ≥5 pus cells per high-power field were observed on microscopic examination of the urine [22].

2.5. Identification and Maintenance of Pure Bacterial Isolates. Identification of bacterial isolates was done on the basis of their cultural and biochemical characteristics. Gram negative bacteria were identified by the standard biochemical tests [14, 23] and Gram positive microorganisms were identified with the corresponding laboratory tests: catalase, coagulase, and mannitol test for *Staphylococcus aureus* [24]. Identified and pure isolates were maintained in nutrient agar slants and incubated at 37°C for 24 hrs. The isolates were subcultured periodically.

2.6. Antibiotic Susceptibility Testing. Isolates were tested for antimicrobial susceptibility testing by the standard Kirby
Bauer’s disc diffusion method [25]. Standard inoculums adjusted to 0.5 McFarland was swabbed on Mueller Hinton agar and was allowed to soak for 2 to 5 minutes. After that antibiotic disks were placed on the surface of media and pressed gently. Mueller Hinton agar plates were then incubated at 37°C for 24 h. After 24 h the inhibition zones were measured and interpreted by the recommendations of clinical and laboratory standards [26]. The following standard antibiotic discs were used for the isolates, ciprofloxacin (CIP), moxifloxacin (MOX), ofloxacin (OFL), sparfloxacin (SPR), levofloxacin (LEV), nalidixic acid (NAL), gatifloxacin (GTX), tobramycin (TOB), amikacin (AMK), gentamycin (GET), ceftazidime (CTZ), cefotaxime (CTX), ceftriaxone (CFX), imipenem (IMP), meropenem (MRP), nitrofurantoin (NTF), netillin (NTL) and co-trimoxazole (COT). Standard strains of *E. coli* (ATCC 25922), *S. aureus* (ATCC 25923), and *P. aeruginosa* (ATCC 27853) were used routinely in this study as control. The mean of triplicates was considered and standard error of mean was calculated by Microsoft Excel ver. 2007.

2.7. Multiple Antibiotic Resistance (MAR) Indexing. The multiple antibiotic resistance indices (MARI) were calculated by the method described by Tambekar et al. [18]. The following formula was used for the calculation of MAR index of antibiotics:

\[
\text{MAR index for an antibiotic} = \frac{\text{number of antibiotics resistant to the isolates}}{\text{number of antibiotics} \times \text{Number of isolates}}
\]

The number of MAR index for an antibiotic indicates its sensitivity and resistance. Antibiotic resistance increases with the increasing MAR values.

2.8. Statistical Analysis. The data were analyzed using Chi-square ($\chi^2$) test, confidence interval (CI), odds ratio (OR) analysis, and student’s $t$-test for paired samples. Relative risk and odds ratio were performed to compare the risk factors in the different groups of interest (male and female patients), and the Chi square test was conducted to find out the significant difference between the isolated uropathogens, infected male and female patients related to different age groups, and statistical comparisons for the MAR indices group; however, $\chi^2$ test for trend was conducted for antimicrobial resistance and sensitivity variables among all isolated uropathogens. The paired $t$-test was used to compare resistance versus sensitivity against isolates. A $P$ value of $<0.05$ was considered as statistically significant for all tests and at 95% level of confidence interval. All statistical tests were performed by Statistical Package for Social Sciences (SPSS) software, Inc. 233 South Wacker Drive, 11th Floor Chicago, IL 60606-6412, USA, for Windows, version 20. The $\chi^2$ test for trend and graphs were prepared by GraphPad PRISM software (version 5.03), Inc. 2236 Avenida de la Playa La Jolla, CA 92037, USA.

3. Results

The overall prevalence of UTI in both male and female patients was found to be 53.82%. Total 155 urine samples showed the significant bacterial growth which were comprised of 52 (35.14%) samples from males and 103 (73.57%) from females. These results indicated that the prevalence of UTI was higher in female patients than in males. The $P$ value and the odds ratio showed a significant variation between male and female patients (Table 1).

The highest susceptible age group of patients to UTI was $\geq$48 years (63.51%) followed by 26–36 years (58.11%), 15–25 years (54.55%), and 37–47 years (39.19%). Comparatively, however, more cases of UTI were observed in females than in males in all age groups. The highest prevalence of UTI in females was found in the age group of 26–36 years (90.69%); however in males the highest susceptible age group to UTI was $\geq$48 years (71.15%). The Chi square test showed statistically significant variations ($P < 0.05$) at 95% level of confidence interval for the infected and not infected male and female patients variables among all age groups. For the infected and not infected male patients variable the Chi-square test values were $\chi^2 = 13.081$; degree of freedom = 1; $P = 0.000$ and the values for infected and not infected female patients were $\chi^2 = 31.114$; degree of freedom = 1; $P = 0.000$ (Table 2). The highest female to male ratio for the occurrence of UTI was found in the age group of 15–25 years (17:1) followed by 26–36 years (9.75:1), 37–47 years (2.22:1), and $\geq$48 years (0.27:1). The $\chi^2$ test for trend results showed significant variations ($P < 0.05$) between the female to male ratio variables in all age groups at 95% confidence interval level ($\chi^2 = 5.228$; degree of freedom = 1; $P = 0.0222$) (Figure 1).

A total of 155 bacterial uropathogens comprised of 140 (90.32%) Gram negative and 15 (9.68%) Gram positive were isolated from positive urine samples. *Escherichia coli* was found the dominant bacteria among all isolated uropathogens with the prevalence rate of 42.58%. The second most prevalent isolate was *Klebsiella pneumoniae* (18.71%) followed by *Pseudomonas aeruginosa* (12.90%), *Staphylococcus aureus* (9.68%), *Proteus* spp. (9.03%), and *Enterobacter* spp. (7.10%). There was no statistically significant variation ($P > 0.05$) was found among the isolates (Table 3). Out of 140 Gram negative bacteria 50 (35.71%) were isolated from males and 90 (64.29%) were from female patients. Only 2 (13.33%) gram positive bacteria were isolated from male and 13 (86.67%)
Table 1: Distribution of significant and nonsignificant growth pattern of screened urinary samples.

| Gender | Tested N | No significant growth (<10^5 cfu/mL) | Significant growth (>10^5 cfu/mL) | Odds ratio | Relative risk | Pearson Chi-square value | P value |
|--------|-----------|-------------------------------------|-----------------------------------|------------|---------------|-------------------------|---------|
|        | N         | %                                   | %                                 | Value      | 95% CI Lower  | 95% CI Upper            |         |
| Male   | 148       | 96                                  | 64.86                             | 52         | 35.14         | 0.195 0.000 0.322       | 0.000† 42.764; df = 1 |
| Female | 140       | 37                                  | 26.43                             | 103        | 73.57         | 0.195 0.000 0.322       | 0.000† 42.764; df = 1 |
| Total  | 288       | 133                                 | 46.18                             | 155        | 53.82         |                         |         |

N: number; %: percentage; CI: confidence interval; df: degree of freedom; † significant.
### Table 2: Prevalence of UTI in different age groups and genders.

| Age group (in years) | Males | Females | Total | Number of not infected males and females (%) | Number of not infected males and females (%) | Number of infected males and females (%) | Number of infected males and females (%) | UTI percentage |
|----------------------|-------|---------|-------|---------------------------------------------|---------------------------------------------|------------------------------------------|------------------------------------------|----------------|
| 15–25                | 25    | 2 (8%)  | 23 (92%) | 41                                          | 34 (82.93%)                                 | 7 (17.07%)                                | 66                                        | 30 (45.45%)    | 36              | 54.55%          |
| 26–36                | 31    | 4 (12.90%) | 27 (87.10%) | 43                                          | 39 (90.69%)                                 | 4 (9.30%)                                 | 74                                        | 31 (41.89%)    | 43              | 58.11%          |
| 37–47                | 40    | 9 (22.5%)  | 31 (77.5%) | 34                                          | 20 (58.82%)                                 | 14 (41.18%)                                | 74                                        | 45 (60.81%)    | 29              | 39.19%          |
| ≥48                  | 52    | 37 (71.15%) | 15 (28.85%) | 22                                          | 10 (45.45%)                                 | 12 (45.45%)                                | 74                                        | 27 (36.49%)    | 47              | 63.51%          |

Statistically significant at $P < 0.05$. 
Table 3: Distribution frequency of isolated bacterial uropathogens.

| Bacterial pathogens       | Frequency (%) | $\chi^2$ value | $P$ value |
|---------------------------|---------------|----------------|-----------|
| *Escherichia coli*        | 66 (42.58%)   |               |           |
| *Klebsiella pneumoniae*   | 29 (18.71%)   |               |           |
| *Pseudomonas aeruginosa*  | 20 (21.90%)   |               |           |
| *Proteus* spp.            | 14 (9.03%)    |               |           |
| *Enterobacter* spp.       | 11 (7.10%)    | 30.000        | 0.224     |
| Total Gram negative       | 140 (90.32%)  |               |           |
| *Staphylococcus aureus*   | 15 (9.68%)    |               |           |
| Total Gram positive       | 15 (9.68%)    |               |           |
| Total Gram negative and positive | 155 (100%) |               |           |

Table 4: Distribution of uropathogens in relation to sex and age of patients.

| Uropathogens     | Number | 15–25 | 26–36 | 37–47 | ≥48 |
|------------------|--------|-------|-------|-------|-----|
|                  |        | Male  | Female | Male  | Female | Male  | Female | Male  | Female |
| *E. coli*        | 66     | 2 (3.03%) | 14 (21.21%) | 3 (4.55%) | 1 (16.67%) | 7 (10.61%) | 5 (7.57%) | 20 (30.30%) | 4 (6.06%) |
| *K. pneumoniae*  | 29     | —     | 11 (37.93%) | 1 (3.45%) | 7 (24.14%) | 1 (3.45%) | 2 (6.89%) | 6 (20.69%) | 1 (3.45%) |
| *P. aeruginosa*  | 20     | —     | 2 (10.00%) | —     | 7 (35.00%) | 1 (5.00%) | 4 (20.00%) | 4 (20.00%) | 2 (10.00%) |
| *Proteus* spp.   | 14     | —     | 1 (7.14%) | —     | 4 (28.57%) | —     | 5 (35.71%) | 3 (21.43%) | 1 (7.14%) |
| *Enterobacter* spp. | 11     | —     | 3 (27.27%) | —     | 5 (45.45%) | —     | 2 (18.18%) | 1 (9.09%) |           |
| *S. aureus*      | 15     | —     | 3 (20.00%) | —     | 5 (33.33%) | —     | 4 (26.67%) | 2 (13.33%) | 1 (6.67%) |
| Total            | 155    | 2     | 34     | 4     | 39    | 9     | 20     | 37     | 10     |

were isolated from female patients. The highest number of gram positive and negative uropathogens (39) was found in the female patients of the age group 26–36 years followed by 37 uropathogens which were isolated from the male patients with the age group of ≥48 years (Table 4).

The highest to lowest prevalence rate for the occurrence of different isolated uropathogens within the age groups were as follows: *E. coli*—≥48 years (36.36%); 15–25 years (24.24%); 26–36 years (21.21%); 37–47 years (18.18%); *K. pneumoniae*—15–25 years (37.93%); 26–36 years (27.59%); ≥48 years (24.14%); 37–47 years (10.34%); *P. aeruginosa*—26–36 years (35.00%); ≥48 years (30.00%); 37–47 years (25.00%); 15–25 years (10.00%); *Proteus* spp.—37–47 years (35.71%); ≥48 years and 26–36 years (28.57%); 15–25 years (7.14%); *Enterobacter* spp.—26–36 years (45.45%); ≥48 years and 26–36 years (27.27%); 37–47 years (0.00%); *S. aureus*—26–36 years (33.33%); 37–47 years (26.67%); ≥48 years and 15–25 years (20.00%) (Figure 2).

Antibiotic susceptibility results showed the resistant and susceptible antibiotics for the tested uropathogens. Overall NAL was found the most resistant drug as 122 (78.71%) uropathogens were found resistant against NAL. The second most resistant drug was CTZ (71.61%) followed by CTX (67.74%); however, the most sensitive drug against all uropathogens was MRP (92.26%) followed by IMP (84.52%), LEV, and NTL each showing 74.84% sensitivity (Figure 3).

The highest MAR index was found for NAL (0.044) followed by CTZ (0.039) and CTX (0.038) indicating that these antibiotics were highly resistant among all tested uropathogens; however, the lowest MAR index was found for both carbapenems MRP and IMP which were 0.004 and 0.000 respectively.

TOB was found the highest resistant drug against 96.97% *E. coli* followed by NAL (90.91%) and CTX (87.88%); however, both carbapenems IMP and MRP showed the highest sensitivity against 98.45% and 95.45% *E. coli*. 79.31% of *K. pneumoniae* were resistant against CTZ and LEV was found the most susceptible drug with the rate of 89.66%. In case of *P. aeruginosa* the highest resistant and susceptible antibiotics were SPR (100%), and MRP (100% respectively. 92.86% of tested *Proteus* spp. were resistant against CFX and 100% sensitive against both carbapenems (IMP and MRP). *Enterobacter* spp. showed 81.82% resistance against CFX and 100% sensitive against both carbapenems (IMP and MRP). All *S. aureus* (100%) showed resistance against NAL and CTX; however, IMP was found 100% sensitive followed by SPR, CFX, and NTL (each showed 93.33% sensitivity against *S. aureus* isolates) (Table 5). The results of the paired $t$-test showed that there was no statistical significance between *E. coli* resistant versus sensitive variables ($P = 0.876$), *K. pneumoniae* resistant versus sensitive variables ($P = 0.232$), *P. aeruginosa* resistant versus sensitive variables ($P = 0.950$), *Proteus* spp. resistant versus sensitive variables ($P = 0.162$) and *S. aureus* resistant versus sensitive variables ($P = 0.072$), however, *Enterobacter* spp. showed the significant variations between resistant versus sensitive variables ($P = 0.000$).

The highest MAR index was found for NAL (0.044) followed by CTZ (0.039) and CTX (0.038) indicating that these antibiotics were highly resistant among all tested uropathogens; however, the lowest MAR index was found for both carbapenems MRP and IMP which were 0.004 and 0.000 respectively.
The occurrence of UTI recorded among the elderly (≥48 years, 63.51%) compared to young age patients (26–37 years, 58.11%; 15–25 years, 54.55%) and middle-age patients (37–47 years, 39.19%) in this study differs from the other studies done in Kuwait [48] and Nigeria [49] in which the highest incidence of UTI was recorded among the age group 20 to 50 years (63.4 and 74.7%, resp.) and lowest among the age group >50 years (13.3 and 10.3%, resp.). However, our results agree with the study done in Japan with a 20-year period in which a trend of increasing complicated UTI was reported in elderly patients [50]. In our study it was found that the elderly males (≥48 years) had a higher incidence of UTI (71.15%) when compared with the elderly females (45.45%). This finding is similar to a study conducted at a tertiary care hospital in

0.008, respectively, indicating the highest sensitivity against uropathogens. The \( \chi^2 \) test results showed no statistically significant variation among the MAR indices of all tested antibiotics (\( \chi^2 = 1.556 \); degree of freedom = 15; \( P = 1.000 \)).

4. Discussion

This study provides valuable data to compare and monitor the status of antimicrobial resistance among uropathogens to improve efficient empirical treatment. Increasing antimicrobial resistance has been documented globally [27–33]. The prevalence of UTI was found to be 53.82% in this study and this rate of prevalence is higher than in the other studies which accounts for 25.6% [34], 22% [35], 38.6% [36], 35.5% [11], 4.2% [37], 17.19% [20], 10.86% [21], 34.5% [38], and 36.68% [39] in India; however, the prevalence rate of UTI in our study correlates with other studies done in South Trinidad [40], and in the Mexican population [41] which showed such more highly significant uropathogens 49% and 97.3%, respectively.

Our study showed a high prevalence of UTI in females (73.57%) than in males (35.14%) which correlates with other findings which revealed that the frequency of UTI is greater in females as compared to males [6, 30, 40–44]. The reason behind this high prevalence of UTI in females is due to close proximity of the urethral meatus to the anus, shorter urethra, sexual intercourse, incontinence, and bad toilet [45–47].
Table 5: Resistant and susceptibility rates (%) for isolated uropathogens.

| Antibiotics | E. coli (66) | K. pneumonia (29) | P. aeruginosa (20) | Proteus spp. (14) | Enterobacter spp. (11) | S. aureus (15) |
|-------------|--------------|-------------------|--------------------|-------------------|----------------------|----------------|
|             | %R | %S | %R | %S | %R | %S | %R | %S | %R | %S | %R | %S | %R | %S |
| CIP         | 69.69 | 30.30 | 79.31 | 20.69 | 5 | 95 | 35.71 | 64.29 | 18.18 | 81.82 | 33.33 | 60.00 |
| MOX         | 56.06 | 40.91 | 58.62 | 41.38 | NT | NT | 42.86 | 50.00 | 9.09 | 90.91 | 60.00 | 40.00 |
| OFL         | 40.91 | 56.06 | 6.89 | 82.76 | 15 | 85 | 57.14 | 42.86 | 0 | 100 | 13.33 | 86.67 |
| SPR         | 37.88 | 56.06 | 51.72 | 48.28 | 100 | 0 | 21.43 | 78.57 | 0 | 100 | 6.67 | 93.33 |
| LEV         | 27.27 | 66.67 | 10.34 | 89.66 | 40 | 60 | 14.29 | 85.71 | 0 | 100 | 26.67 | 73.33 |
| NAL         | 90.91 | 90.91 | 17.24 | 82.76 | 95 | 5 | 28.57 | 71.43 | 18.18 | 81.82 | 20.00 | 80.00 |
| GTX         | 60.61 | 39.39 | 20.69 | 79.31 | NT | NT | 50.00 | 50.00 | 9.09 | 81.82 | 33.33 | 66.67 |
| TOB         | 96.97 | 3.03 | 68.97 | 31.03 | 60 | 40 | 71.43 | 28.57 | 27.27 | 72.73 | 20.00 | 73.33 |
| AMK         | 9.09 | 90.91 | 17.24 | 82.76 | 95 | 5 | 28.57 | 71.43 | 18.18 | 81.82 | 20.00 | 80.00 |
| GET         | 68.18 | 30.30 | 34.48 | 65.52 | 10 | 90 | 21.43 | 71.43 | 9.09 | 90.91 | 13.33 | 80.00 |
| CTZ         | 78.79 | 18.18 | 79.31 | 13.79 | 65 | 35 | 78.57 | 21.43 | 45.45 | 54.55 | 46.67 | 53.33 |
| CFX         | 87.88 | 10.61 | 90.54 | 9.46 | 60 | 40 | 71.43 | 28.57 | 27.27 | 72.73 | 20.00 | 73.33 |
| IMP         | 53.03 | 46.97 | 20.69 | 79.31 | 95 | 5 | 92.86 | 7.14 | 0 | 100 | 0 | 100 |
| MRP         | 0 | 98.48 | 58.62 | 41.38 | 5 | 95 | 0 | 100 | 0 | 100 | 0 | 100 |
| NTF         | 4.55 | 95.45 | 13.79 | 86.21 | 0 | 100 | 0 | 100 | 0 | 100 | 20.00 | 80.00 |
| NTL         | 25.76 | 74.24 | 62.07 | 37.93 | 90 | 10 | 57.14 | 42.86 | 81.82 | 18.18 | 6.67 | 93.33 |
| COT         | 84.85 | 15.15 | 80.48 | 19.52 | 60 | 40 | 85.71 | 14.29 | 36.36 | 62.64 | 6.67 | 93.33 |

CIP: ciprofloxacin; MOX: moxifloxacin; OFL: ofloxacin; SPR: sparfloxacin; LEV: levofloxacin; NAL: nalidixic acid; GTX: gatifloxacin; TOB: tobramycin; AMK: amikacin; GET: gentamycin; CTZ: ceftriaxone; CFX: cefotaxime; IMP: imipenem; MRP: meropenem; NTF: nitrofurantoin; NTL: netilin; COT: co-trimoxazole; R: resistant; S: sensitive; NT: not Tested.
The sensitivity rate of carbepenems among uropathogens was as follows: *E. coli* (MRP; 95.45% and IMP; 98.89%), *P. aeruginosa* (MRP; 100% and IMP; 95.00%), *Proteus* spp. (MRP; 100% and IMP; 100%), *Enterobacter* spp. (MRP; 100% and IMP; 100%), and *S. aureus* (MRP; 80% and IMP; 100%), followed by LEV and NTL each of which showed 74.84% sensitivity, however, *K. pneumonia* did not show a high susceptibility to IMP (24.14%) but it was susceptible to MRP (86.21%). These antibiotic susceptibility results correlate with other studies [76, 77]. Another study conducted in India showed that meropenem was highly sensitive against Gram negative bacilli whereas cephalosporin showed highest resistance against gram negative rods [78]. In other study, meropenem and imipenem were found to be 98% and 100% sensitive, respectively, against highly resistant gram negative bacilli [79]. A study done in King Fahd Hospital, Saudi Arabia showed that meropenem was 95.8% sensitive followed by amikacin (93.7%) and imipenem (91.71%) against extended spectrum β lactamase producing *E. coli* [80].

Tested fluoroquinolones in this study showed the highest resistance among uropathogens as in *E. coli*; NAL (90.91%); *K. pneumoniae*; CIP (79.31%), *P. aeruginosa*; SPR (100%), and *S. aureus*; NAL (100%); however, III generation cephalosporin showed the highest resistance in *K. pneumoniae*; CTZ (79.31%) the *Proteus* spp.; CFX (92.86%), and *S. aureus*; CTX (100%). This high rate of resistance against fluoroquinolones was also suggested by other studies done in Spain, Europe, and Iran [33, 81] and also by other studies done in India [21, 44, 82]. Another study done in Spain also showed the reduced susceptibility of *E. coli* isolates from patients with UTI to Fluoroquinolones (16%) [81]. This reduced susceptibility might be due to using antibiotics without restriction. In several studies it has been shown that the highly prescribing habits of the physicians are the driving factor for the antibiotic resistance for this group of antibiotic [83–85]. McEwen et al. [86] found that 37% of physicians actually prescribe trimethoprim-sulphamethoxazole closely followed by fluoroquinolones (32%) and the average duration of antibiotic therapy is 8.6 days in the United States which is the best example of this problem; empiric use of fluoroquinolones should be restricted and founding the strategies against increasing resistance of pathogens to these antibiotics should be done.

Our finding about the Fluoroquinolones did not correlate with others which showed that they were highly effective (sensitive) [11, 55, 64, 87, 88]. For these organisms, drugs with inhibitors like Augmentin may be tried [89] but such drugs should be reserved for the last line of treatment. The alarming finding in this study is the resistance to third-generation cephalosporin; the highest resistance was seen against CTZ (71.61%) followed by CTX (67.74%) among all uropathogens. This is an indication that many of the organisms are ESBL producers [90]. The other possible explanation behind this situation is that the III generation cephalosporin has been in use for a long period and must have been abused and over time organisms have developed resistant mechanisms due to changing their mode of action. The inappropriate usage of wide spectrum antibiotics, insufficient hygiene, immunosuppression, and a prolonged stay in the hospital are some other major etiological factors that elevate the chances of MDR infections [89].
5. Conclusion

Against the background of paucity of reports of UTI in Meerut city (Uttar Pradesh), India, this is the first study conducted to determine the prevalence of UTI, the effect of gender and age on its prevalence, and their susceptibility profile in the community of Meerut city. This study provides valuable laboratory data to monitor the status of antimicrobial resistance among uropathogens and to improve treatment recommendations in a specific geographical region. The study also allows comparison of the situation in Meerut with other regions within and outside the state as well as in the country.

Conflict of Interests

The authors have declared that there are no competing interests.

Acknowledgments

The authors are grateful to the OPD physicians and technical staffs of hospital laboratories for their guidance and efforts. They are also thankful to the hospital administrations for granting them permission for sample collection from UTI patients and to the Head, Department of Botany, Meerut College, Meerut (U.P.), India, for providing the necessary facilities to carry out this work. The authors are also thankful to the University Grants Commission for their financial support to carry out this research work.

References

[1] C. M. Gonzalez and A. J. Schaeffer, “Treatment of urinary tract infection: what’s old, what’s new, and what works,” World Journal of Urology, vol. 17, no. 6, pp. 372–382, 1999.

[2] I. Zelikovic, R. D. Adelman, and P. A. Nancarrow, “Urinary tract infections in children—an update,” Western Journal of Medicine, vol. 157, no. 5, pp. 554–561, 1992.

[3] J. D. Sobel and D. Kaye, “Urinary tract infections,” in Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases, G. L. Mandell, J. E. Bennett, and R. Dolin, Eds., pp. 957–985, Churchill Livingstone, Philadelphia, Pa, USA, 7th edition, 2010.

[4] S. M. Sabra and M. M. Abdel-Fattah, “Epidemiological and microbiological profile of nosocomial infection in Taif hospitals, KSA (2010-2011),” World Journal of Medical Sciences, vol. 7, no. 1, pp. 1–9, 2012.

[5] J. W. Warren, E. Abrutyn, J. Richard Hebel, J. R. Johnson, A. J. Schaeffer, and W. E. Stamm, “Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women,” Clinical Infectious Diseases, vol. 29, no. 4, pp. 745–758, 1999.

[6] A. J. Schaeffer, N. Rajan, Q. Cao et al., “Host pathogenesis in urinary tract infections,” International Journal of Antimicrobial Agents, vol. 17, no. 4, pp. 245–251, 2001.

[7] E. E. Akortha and O. K. Ibadin, “Incidence and antibiotic susceptibility pattern of Staphylococcus aureus amongst patients with urinary tract infection (UTI) in UBTH Benin City, Nigeria,” African Journal of Biotechnology, vol. 7, no. 11, pp. 1637–1640, 2008.

[8] K. C. Arul, K. G. Prakasam, D. Kumar, and M. Vijayan, “A cross sectional study on distribution of urinary tract infection and their antibiotic utilization pattern in Kerala,” International Journal of Pharmaceutical and Biomedical Sciences, vol. 3, no. 3, pp. 1125–1130, 2012.

[9] M. J. Lucas and F. G. Cunningham, “Urinary infection in pregnancy,” Clinical Obstetrics and Gynecology, vol. 36, no. 4, pp. 855–868, 1993.

[10] J. W. Warren, J. H. Tenney, and J. M. Hoopes, “A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters,” Journal of Infectious Diseases, vol. 146, no. 6, pp. 719–723, 1982.

[11] M. Y. Ebie, Y. T. Kandaki-Olukemi, J. Ayanbadejo, and K. B. Tanyigna, “UTI infections in a Nigerian Military Hospital,” Nigerian Journal of Microbiology, vol. 15, no. 1, pp. 31–37, 2001.

[12] A. S. Kolawole, O. M. Kolawole, Y. T. Kandaki-Olukemi, S. K. Babatunde, K. A. Durowade, and C. F. Kolawole, “Prevalence of urinary tract infections (UTI) among patients attending Dahatu Araf Specialist Hospital, Lafia, Nasarawa State, Nigeria,” International Journal of Medicinal Medical Sciences, vol. 1, no. 5, pp. 163–167, 2009.

[13] I. O. Okonko, L. A. Ijandipe, O. A. Ilusanya et al., “Incidence of urinary tract infection (UTI) among pregnant women in Ibadan, South-Western Nigeria,” African Journal of Biotechnology, vol. 8, no. 23, pp. 6649–6657, 2009.

[14] B. Foxman and P. Brown, “Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs,” Infectious Disease Clinics of North America, vol. 17, no. 2, pp. 227–241, 2003.

[15] J. J. Alós, “Epidemiology and etiology of urinary tract infections in the community. Antimicrobial susceptibility of the main pathogens and clinical significance of resistance,” Enfermedades Infecciosas y Microbiologia Clinica, vol. 23, no. 4, pp. 3–8, 2005.

[16] C. A. M. McNulty, J. Richards, D. M. Livermore et al., “Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care,” Journal of Antimicrobial Chemotherapy, vol. 58, no. 5, pp. 1000–1008, 2006.

[17] J. Car, “Urinary tract infections in women: diagnosis and management in primary care,” British Medical Journal, vol. 332, no. 7533, pp. 94–97, 2006.

[18] D. H. Tambekar, D. V. Dhanorkar, S. R. Gulhane, V. K. Khandelwal, and M. N. Dudhane, “Antibacterial susceptibility of some urinary tract pathogens to commonly used antibiotics,” African Journal of Biotechnology, vol. 5, no. 17, pp. 1562–1565, 2006.

[19] D. Biswas, P. Gupta, R. Prasad, V. Singh, M. Arya, and A. Kumar, “Choice of antibiotic for empirical therapy of acute cystitis in a setting of high antimicrobial resistance,” Indian Journal of Medical Sciences, vol. 60, no. 2, pp. 53–58, 2006.

[20] M. Akram, M. Shahid, and A. U. Khan, “Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India,” Annals of Clinical Microbiology and Antimicrobials, vol. 6, article 4, 2007.

[21] A. Kothari and V. Sagar, “Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study,” The Journal of Infection in Developing Countries, vol. 2, no. 5, pp. 354–358, 2008.

[22] J. G. Collee, R. S. Miles, and B. Watt, “Tests for the identification of bacteria,” in Mackie and Mc Artney Practical Medical Microbiology, J. G. Collee, A. G. Fraser, B. P. Marimuth, and A. Simmons, Eds., p. 433, Churchill Livingstone, London, UK, 1996.
Bacteriology of Urinary Tract Infection amongst V. Rajalakshmi and V. Amsaveni, "Antibiotic susceptibility of K.O. Akinyemi, S.A. Alabi, M. A. Taiwo, and E. A. Omonigbe-

[23] B. Foxman, R. Barlow, H. D'Arcy, B. Gillespie, and J. D. Sobel, "Urinary tract infection: self-reported incidence and associated costs," Annals of Epidemiology, vol. 10, no. 8, pp. 509–515, 2000.

[24] A. Andrea, J. I. Alós, M. Gobernado, F. Marco, M. De La Rosa, and J. A. García-Rodríguez, "Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study," Enfermedades Infecciosas y Microbiología Clínica, vol. 23, no. 1, pp. 4–9, 2005.

[25] A. W. Bauer, W. M. Kirby, J. C. Sherris, and M. Turck, "Antibiotic susceptibility testing by a standardized single disk method," American Journal of Clinical Pathology, vol. 45, no. 4, pp. 493–496, 1966.

[26] Clinical and Laboratory Standards Institute (CLSI), "Document M100-S17. Performance standards for antimicrobial susceptibility testing," CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087–1898, USA, 2007.

[27] M. Jani, S. Shah, and S. Prajapati, "Antibacterial screening and qualitative phytochemical estimation of selected aquatic plants," Advances in Biological Research, vol. 6, no. 1, pp. 19–23, 2012.

[28] N. Kashef, G. E. Djavid, and S. Shahbazi, "Antimicrobial susceptibility patterns of community-acquired uropathogens in Tehran, Iran," The Journal of Infection in Developing Countries, vol. 4, no. 4, pp. 202–206, 2010.

[29] J. A. Karlowsky, M. E. Jones, C. Thornsberry, I. Critchley, L. J. Kelly, and D. F. Sahm, "Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999," International Journal of Antimicrobial Agents, vol. 18, no. 2, pp. 121–127, 2001.

[30] V. Rajalakshmi and V. Amsaveni, "Antibiotic susceptibility of bacterial pathogens isolated from diabetic patients," International Journal of Microbiological Research, vol. 3, no. 1, pp. 30–32, 2012.

[31] M. Sharifian, A. Karimi, S. R. Tabatabaei, and N. Anvaripour, "Microbial sensitivity pattern in urinary tract infections in children: a single center experience of 1,177 urine cultures," Japanese Journal of Infectious Diseases, vol. 59, no. 6, pp. 380–382, 2006.

[32] M. Haghi-Ashteiiani, N. Sadeghiifrard, M. Abedini, S. Sorouch, and M. Taheri-Kalani, "Etiology and antibacterial resistance of bacterial urinary tract infections in children's medical center, Tehran, Iran," Acta Medica Iranica, vol. 45, no. 2, pp. 153–157, 2007.

[33] F. R. M. Rashedmarandi and M. Saremi, "A survey on urinary pathogens and their antimicrobial susceptibility among patients with significant bacteriuria," Iranian Journal of Pathology, vol. 3, pp. 191–196, 2008.

[34] Nedolisa, Bacteriology of Urinary Tract Infection amongst Patients Attending Jos University Teaching Hospital (JUTH)1998 [M.S. thesis], University of Jos, Jos, Nigeria.

[35] C. C. Ekweozor and T. N. Onyemenen, "Urinary Tract Infection in Ibadan, Nigeria: causative organism and anti-microbial sensitivity pattern," African Journal of Medical Sciences, vol. 25, pp. 165–169, 1996.

[36] K. O. Akinleyemi, S. A. Alabi, M. A. Taiwo, and E. A. Omonigbehin, "Antimicrobial susceptibility pattern and plasmid profiles of pathogenic bacteria isolated from subjects with urinary tract infections in Lagos, Nigeria," Nigerian Quarterly Journal of Hospital Medicine, vol. 1, pp. 7–11, 1997.

[37] E. I. Bigwan and D. Elijah, "Prevalence of Escherichia coli among uropathogens in asymptomatic bacteriuria in a Nigerian Tertiary School in Jos, Nigeria," International Journal of Biomedical and Advance Research, vol. 4, no. 3, pp. 198–202, 2013.

[38] M. Dash, S. Padhi, I. Mohanty, P. Panda, and B. Parida, "Antimicrobial resistance in pathogens causing urinary tract infections in a rural community of Odisha, India," Journal of Family and Community Medicine, vol. 20, no. 1, pp. 20–26, 2013.

[39] M. Mehta, S. Bhardwaj, and J. Sharma, "Screening of urinary isolates for the prevalence and antimicrobial susceptibility of Enterobacteria other than Escherichia coli," International Journal of Life Science and Pharma Research, vol. 3, no. 1, pp. 100–104, 2013.

[40] F. A. Orrett, "Urinary tract infections in general practice in a rural community in South Trinidad," Saudi Medical Journal, vol. 22, no. 6, pp. 537–540, 2001.

[41] A. García-Morúa, A. Hernández-Torres, J. L. Salazar-de-Hoyos, R. Jaime-Dávila, and L. S. Gómez-Guerra, "Community acquired urinary tract infection etiology and antibiotic resistance in a Mexican population group," Revista Mexicana de Urología, vol. 69, pp. 45–48, 2009.

[42] H. W. Boucher, G. H. Talbot, J. S. Bradley et al., "Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America," Clinical Infectious Diseases, vol. 48, no. 1, pp. 1–12, 2009.

[43] B. Henry Oladeinde, R. Omoregie, M. Olley, and J. A. Anunibe, "Urinary tract infection in a rural community of Nigeria," North American Journal of Medical Sciences, vol. 3, no. 2, pp. 75–77, 2011.

[44] S. Sood and R. Gupta, "Antibiotic resistance pattern of community acquired uropathogens at a tertiary care hospital in Jaipur, Rajasthan," Indian Journal of Community Medicine, vol. 37, no. 1, pp. 39–44, 2012.

[45] J. Ochei and A. Kolhatkar, "Diagnosis of infection by specific anatomic sites/antimicrobial susceptibility tests," in Medical Laboratory Science Theory and Practice, pp. 615–643, 788–798, McGraw-Hill, New Delhi, India, 6th edition, 2007.

[46] O. A. Aiyegoro, O. O. Igbinosoa, I. N. Ogummwnyo, E. Odjad-jaro, O. E. Igbinosob, and A. I. Okoh, "Incidence of urinary tract infections (UTI) among children and adolescents in Ille-Ife, Nigeria," African Journal of Microbiological Research, vol. 1, pp. 13–19, 2007.

[47] F. A. Orrett and G. K. Davis, "A comparison of antimicrobial susceptibility profile of urinary pathogens for the years, 1999 and 2003," West Indian Medical Journal, vol. 55, no. 2, pp. 95–99, 2006.

[48] T. S. Dimitrov, E. E. Udo, F. Awini, M. Emara, and R. Passadilla, "Etiology and antibiotic susceptibility patterns of community-acquired urinary tract infections in a Kuwait Hospital," Medical Principles and Practice, vol. 13, no. 6, pp. 334–339, 2004.

[49] O. Omigie, L. Okoror, P. Umolu, and G. Ikuuhe, "Increasing resistance to quinolones: a four-year prospective study of urinary tract infection pathogens," International Journal of General Medicine, vol. 2, pp. 171–175, 2009.

[50] K. Shigemura, K. Tanaka, H. Okada et al., "Pathogen occurrence and antimicrobial susceptibility of urinary tract infection cases during a 20-year period (1983-2002) at a single institution in Japan," Japanese Journal of Infectious Diseases, vol. 58, no. 5, pp. 303–308, 2005.

[51] R. N. Das, T. S. Chandrashekhar, H. S. Joshi, M. Gurung, N. Shrestha, and P. G. Shivananda, "Frequency and susceptibility...
profile of pathogens causing urinary tract infections at a tertiary care hospital in western Nepal,” Singapore Medical Journal, vol. 47, no. 4, pp. 281–285, 2006.

[52] S. Shankel, Urinary Tract Infections Genitourinary Disorders, The Merck Manuals Online Medical Library, 2007.

[53] F. A. Orrett and S. M. Shurland, “The changing patterns of antimicrobial susceptibility of urinary pathogens in Trinidad,” Singapore Medical Journal, vol. 39, no. 6, pp. 256–259, 1998.

[54] A. C. Gales, R. N. Jones, K. A. Gordon et al., “Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998),” Journal of Antimicrobial Chemotherapy, vol. 45, no. 3, pp. 295–303, 2000.

[55] M. Theodore, “Prevalence and antibiogram of urinary tract infections among prison inmates in Nigeria,” African Journal of Microbiological Research, vol. 6, no. 4, pp. 414–420, 2012.

[56] B. A. M. Adedeji and O. A. Abdulkadir, “Etiology and antimicrobial resistance pattern of bacterial agents of urinary tract infections in students of tertiary institution in Yola metropolis,” Advances in Biological Research, vol. 3, no. 4, pp. 67–70, 2009.

[57] A. N. Kebira, P. Ochola, and S. A. Khamadi, “Isolation and antimicrobial susceptibility testing of Escherichia coli causing urinary tract infections,” Journal of Applied Biosciences, vol. 22, pp. 1320–1325, 2009.

[58] I. Shaifali, U. Gupta, S. E. Mahmood, and J. Ahmed, “Antibiotic susceptibility patterns of urinary pathogens in female outpatients,” North American Journal of Medical Sciences, vol. 4, no. 4, pp. 163–169, 2012.

[59] T. M. Hooton, D. Scholes, J. P. Hughes et al., “A prospective study of risk factors for symptomatic urinary tract infection in young women,” The New England Journal of Medicine, vol. 335, no. 7, pp. 468–474, 1996.

[60] E. Kalantar, M. E. Motlagh, H. Lornejad, and N. Reshadmanesh, “Prevalence of urinary tract pathogens and antimicrobial susceptibility patterns in children at hospitals in Iran,” Iranian Journal of Clinical Infectious Diseases, vol. 3, no. 3, pp. 149–153, 2008.

[61] R. N. Gruneberg, “Antibiotic sensitivities of urinary pathogens, 1971–1978,” Journal of Clinical Pathology, vol. 33, no. 9, pp. 853–856, 1980.

[62] R. Daza, J. Gutiérrez, and G. Piquedola, “Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections,” International Journal of Antimicrobial Agents, vol. 18, no. 3, pp. 211–215, 2001.

[63] E. M. Abubakar, “Antimicrobial susceptibility pattern of pathogenic bacteria causing urinary tract infections at the Specialist Hospital, Yola, Adamawa State, Nigeria,” Journal of Clinical Medicine Research, vol. 1, no. 1, pp. 001–008, 2009.

[64] J. O. Ehnimiu, R. O. Bolaji, and E. E. A. Adegbeye, “Isolation and antibiotic susceptibility profile of Neisseria gonorhoea isolated from urine samples in Zaria, northern Nigeria,” Journal of Phytomedicine and Therapeutics, vol. 8–11, pp. 20–24, 2003.

[65] O. A. Aboderin, L.-R. Abd, B. W. Odetoyin, and A. Lamikanra, “Antimicrobial resistance in Escherichia coli strains from urinary tract infections,” Journal of the National Medical Association, vol. 101, no. 12, pp. 1268–1273, 2009.

[66] N. Al Sweih, W. Jamal, and V. O. Rotimi, “Spectrum and antibiotic resistance of uropathogens isolated from hospital and community patients with urinary tract infections in two large hospitals in Kuwait,” Medical Principles and Practice, vol. 14, no. 6, pp. 401–407, 2005.

[67] J. C. Uwaezuoke and N. Ogbulic, “Antibiotic sensitivity pattern of urinary tract pathogens in Port-Harcourt, Nigeria,” Journal of Applied Sciences and Environmental Management, vol. 10, no. 3, pp. 103–107, 2006.

[68] B. N. Selvakumar and R. Jasmine, “Antibiotic susceptibility of ESBL-producing urinary isolates at a Tertiary Care Hospital in Tiruchirappalli South India,” Journal of Medical Sciences, vol. 7, no. 3, pp. 443–446, 2007.

[69] J. Bahadin, S. S. H. Teo, and S. Mathew, “Aetiology of community-acquired urinary tract infection and antimicrobial susceptibility patterns of uropathogens isolated,” Singapore Medical Journal, vol. 52, no. 6, pp. 415–420, 2011.

[70] K. Bano, J. Khan, R. H. Begum et al., “Patterns of antibiotic sensitivity of bacterial pathogens among urinary tract infections (UTI) patients in a Pakistani population,” African Journal of Microbiological Research, vol. 6, no. 4, pp. 1320–1325, 2009.

[71] S. Nys, T. van Merode, A. J. M. Bartelds, and E. E. Stobberingh, “Urinary tract infections in general practice patients: diagnostic tests versus bacteriological culture,” Journal of Antimicrobial Chemotherapy, vol. 57, no. 5, pp. 955–958, 2006.

[72] S. Nys, T. Van Merode, A. I. M. Bartelds, and E. E. Stobberingh, “Antibiotic treatment and resistance of unselected uropathogens in the elderly,” International Journal of Antimicrobial Agents, vol. 27, no. 3, pp. 236–241, 2006.

[73] S. Nys, “Antibiotic resistance and commensal flora,” in Microbiology, p. 142, University Maastricht, Maastricht, The Netherlands, 2005.

[74] B. A. Lipsky, “Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis and treatment,” Annals of Internal Medicine, vol. 110, no. 2, pp. 138–150, 1989.

[75] B. A. Lipsky, “Prostatitis and urinary tract infection in men: what’s new; what’s true?,” American Journal of Medicine, vol. 106, no. 3, pp. 327–334, 1999.

[76] I. Alipourfard and N. Y. Nili, “Antibiogram of Extended Spectrum Beta-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae isolated from Hospital Samples,” Bangladesh Journal of Medical Microbiologyno, vol. 4, no. 4, pp. 32–36, 2010.

[77] A. Mangaiarikarasi, A. R. Meher, and R. Gopal, “Study of Antimicrobial Susceptibility Pattern of Escherichia coli Isolated from clinical specimens in a Teaching Hospital, Pondicherry,” The Research Journal of Pharmaceutical, Biological and Chemical Sciences, vol. 4, no. 1, pp. 1365–1371, 2013.

[78] N. Goel, U. Chaudhary, R. Aggarwal, and K. Bala, “Antibiotic sensitivity pattern of gram negative bacilli isolated from the lower respiratory tract of ventilated patients in the intensive care unit,” Indian Journal of Critical Care Medicine, vol. 13, no. 3, pp. 148–151, 2009.

[79] M.-L. Joly-Guillou, M. Kempf, J.-D. Cavallo et al., “Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study,” BMC Infectious Diseases, vol. 10, article 1471, 2010.

[80] A. J. Al-Zahran and N. Akhtar, “Susceptibility patterns of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolated in a teaching hospital,” Pakistan Journal of Medical Research, vol. 44, pp. 64–67, 2005.

[81] M. Gobernado, L. Valdés, J. I. Alós, C. García-Rey, R. Dal-Re, and J. García-de-Lomas, “Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in
women over a 1-year period in Spain,” Revista Española de Quimioterapia, vol. 20, no. 1, pp. 68–76, 2007.

[82] E. R. Sabharwal, “Antibiotic susceptibility patterns of uropathogens in obstetric patients,” North American Journal of Medical Sciences, vol. 4, pp. 316–319, 2012.

[83] G. Kahlmeter, “An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS project,” Journal of Antimicrobial Chemotherapy, vol. 51, no. 1, pp. 69–76, 2003.

[84] W. Goettsch, W. Van Pelt, N. Nagelkerke et al., “Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in The Netherlands,” Journal of Antimicrobial Chemotherapy, vol. 46, no. 2, pp. 223–228, 2000.

[85] H. Goossens, M. Ferech, R. Vander Stichele, and M. Elseviers, “Outpatient antibiotic use in Europe and association with resistance: a cross-national database study,” The Lancet, vol. 365, no. 9459, pp. 579–587, 2005.

[86] L. N. McEwen, R. Farjo, and B. Foxman, “Antibiotic prescribing for cystitis: how well does it match published guidelines?” Annals of Epidemiology, vol. 13, no. 6, pp. 479–483, 2003.

[87] P. H. Krumperman, “Multiple antibiotic resistance indexing of Escherichia coli to identify high-risk sources of fecal contamination of foods,” Applied and Environmental Microbiology, vol. 46, no. 1, pp. 165–170, 1983.

[88] K. A. Burbige, A. B. Retic, A. Colony, S. B. Bauer, and R. Lebowitz, “UTI in boys,” Journal of Urology, vol. 132, pp. 541–542, 1984.

[89] G. N. Manjunath, R. Prakash, V. Annam, and K. Shetty, “The changing trends in the spectrum of the antimicrobial drug resistance pattern of uropathogens which were isolated from hospitals and community patients with urinary tract infections in Tumkur and Bangalore,” International Journal of Biological and Medical Research, vol. 2, no. 2, pp. 504–550, 2011.

[90] J. Rodriguez-Baño, M. D. Navarro, L. Romero et al., “Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients,” Journal of Clinical Microbiology, vol. 42, no. 3, pp. 1089–1094, 2004.